DURHAM – Target RWE joins the company’s leadership team, hiring Derek Evans as president.
The company announced the news today in a statement.
“In this new role, Derek will lead all operational functions as we continue to leverage our important software, data and intellectual assets and capabilities for our partners,” said Neal Bibeau, CEO of Target RWE.
The company, which acquired Durham-based software analytics firm NoviSci, Inc. in January 2021, combined the two startups with financial backing in the form of a strategic investment from Amgen. Amgen announced earlier this year that it will build a facility in Holly Springs and hire up to 355 employees in high-paying positions.
Biotech giant Amgen invests after Durham startups merger in health data deal
The company “designs custom datasets, analyzes and evidence to answer the complexities of healthcare evidence questions and quality initiatives,” according to its website. The company can then offer its customers a “turnkey evidence-of-health solution that quickly aggregates real-world data,” it says on its website.
The company is recruiting for other positions as well, as the careers website lists seven vacancies in Durham.
“The RWE goal has taken an important momentum in delivering the promise of concrete evidence to the healthcare sector, to healthcare providers and, most importantly, to patients living with often chronic and co-morbid conditions,” said Derek Evans in a press release.
Life science firm Amgen chooses Holly Springs for factory, hundreds of jobs at $ 120,000
Evans was most recently managing director of business intelligence and innovation at Change Healthcare, a provider of a healthcare analytics platform.
“I am delighted to join the organization at this critical time to accelerate the excellent work that is currently underway,” Evans said in the statement. “Target RWE is on the precipice of healthcare innovation by bringing together unique real-world data, new analytics and cutting-edge technology at scale to improve healthcare outcomes. With our proprietary technology, we can help our customers make better decisions that speed time to market, reduce investment and improve patient outcomes.
Earlier this year, the company announced the addition of Dr. Andrew von Eschenbach as a senior advisor, the company statement said.